Dian Diagnostics Group Co., Ltd. (300244.SZ) has released its Q3 report for 2025, indicating a revenue of 7.566 billion yuan for the first three quarters, a year-on-year decrease of 18.28%. The net profit attributable to shareholders of the listed company stands at 56.7048 million yuan, a decrease of 56.67% year-on-year. The net profit attributable to shareholders, excluding non-recurring gains and losses, is 35.5519 million yuan, reflecting a 73.50% decline compared to the previous year. The basic earnings per share are 0.0928 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments